Makhnov Nikita, Skov Jakob, Åkerström Tobias, Axling Fredrik, Andernord Daniel, Bergenheim Mikael, Waldén Mauritz, Hellman Per
Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
Department of Surgery, Karlstad Central Hospital, Karlstad, Sweden.
Front Endocrinol (Lausanne). 2025 Apr 14;16:1555572. doi: 10.3389/fendo.2025.1555572. eCollection 2025.
Primary aldosteronism (PA) is a common cause of hypertension. It entails elevated morbidity and mortality that do not sufficiently improve with conventional antihypertensive therapy. Screening for PA by plasma aldosterone-renin ratio (ARR) enables discovery and specific treatment of affected patients. By screening primary care patients with hypertension and evaluating them further according to the Endocrine Society guidelines, we aimed to assess the prevalence of PA, the factors affecting biochemical diagnostics, and the outcome of lateralization studies and of specific treatment of the discovered PA cases.
Prospective evaluation of screening for PA was conducted in 1,181 patients. Screening by ARR was performed under current therapy, but without mineralocorticoid receptor antagonists (MRA), under normokalemia, and confirmed by the intravenous saline suppression test, SST#1. Those with results in a defined gray zone underwent therapy adjustment and then completed SST#2. Plasma aldosterone and ARR were compared under different stages of the diagnostic process. All patients with PA were offered adrenal venous sampling, or, in certain cases, adrenocortical-specific positron emission tomography. Lateralizing cases were offered laparoscopic adrenalectomy. Patients with bilateral disease were treated with MRA. Treatment results were assessed after a minimum of 6 months.
A total of 53 discovered cases of (mostly mild) PA corresponded to its prevalence of 4.5%. Initial seated ARR was higher than recumbent ARR before SST#1. At SST#2, initial ARR and final aldosterone were higher than at SST#1. Localizing studies (accepted by 45 patients) found 14 lateralized cases. Of the 11 operated cases, 4 had aldosterone-producing adenoma, and the remainder had micro- and macronodular histopathology. A total of 31 patients had bilateral PA. Both surgical and conservative treatments were well tolerated and led to improved blood pressure and higher renin, indicating risk amelioration.
PA is prevalent among primary care patients with hypertension and can be screened for under current antihypertensive therapy. Aldosterone-producing adenoma was rare in this cohort. The study results support active screening of primary care patients with hypertension for PA in order to offer appropriate treatment options.
原发性醛固酮增多症(PA)是高血压的常见病因。它会导致发病率和死亡率升高,而传统抗高血压治疗并不能充分改善这些情况。通过血浆醛固酮 - 肾素比值(ARR)筛查PA能够发现并对受影响患者进行特异性治疗。通过对原发性高血压初级保健患者进行筛查,并根据内分泌学会指南对他们进行进一步评估,我们旨在评估PA的患病率、影响生化诊断的因素以及定位研究结果和已发现PA病例的特异性治疗结果。
设计、患者与方法:对1181例患者进行PA筛查的前瞻性评估。在当前治疗下但无盐皮质激素受体拮抗剂(MRA)的情况下,在血钾正常时通过ARR进行筛查,并通过静脉盐水抑制试验(SST#1)进行确认。那些结果处于特定灰色区域的患者进行治疗调整,然后完成SST#2。在诊断过程的不同阶段比较血浆醛固酮和ARR。所有PA患者均接受肾上腺静脉采血,或在某些情况下接受肾上腺皮质特异性正电子发射断层扫描。对定位明确的病例进行腹腔镜肾上腺切除术。双侧病变患者接受MRA治疗。至少6个月后评估治疗结果。
共发现53例(大多为轻度)PA病例,患病率为4.5%。在SST#1之前,初始坐位ARR高于卧位ARR。在SST#2时,初始ARR和最终醛固酮高于SST#1。定位研究(45例患者接受)发现14例定位明确的病例。在11例手术病例中,4例为醛固酮瘤,其余为微结节和大结节组织病理学。共有31例患者为双侧PA。手术和保守治疗耐受性良好,血压改善,肾素升高,表明风险降低。
PA在原发性高血压初级保健患者中普遍存在,并且可以在当前抗高血压治疗下进行筛查。该队列中醛固酮瘤罕见。研究结果支持对原发性高血压初级保健患者积极筛查PA,以便提供合适的治疗选择。